Laura Codari Deak

Company: Roche Innovation Center
Job title: Team & Research Project Leader, Principal Scientist
Seminars:
A Novel Bispecific Checkpoint Inhibitor Antibody to Preferentially Block PD-1 & LAG-3 on TILs Whilst Sparing Treg Activation 9:30 am
Improved targeting to tumor-reactive T-cells rather than Tregs due to the selectivity gain and different expression patterns of PD-1 and LAG-3 on these two T-cell types Reduced internalization Fc silent-mediated resistance to drug-shaving by macrophages Increased in vitro T-cell effector functions even in the presence of Tregs, and Superiror in vivo tumor control/eradication in several…Read more
day: Day One